Boston Scientific Inks Paclitaxel Supply Deal With Natural Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's exclusive paclitaxel supply agreement with Natural Pharmaceuticals complements an earlier licensing agreement with Angiotech Pharmaceuticals covering the drug's application on coronary stents and other products.